Semaphore

Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results

Retrieved on: 
onsdag, april 10, 2024
FDA, Drug discovery, Synovitis, Cell, Research, Vaccine, IND, Nanoparticle, Allergic rhinitis, DNMT3B, Dicarboxylic acid, Inflammation, Hearing loss, Osteoarthritis, Vertigo, RNA, Myocardial infarction, Patent, CHF, Messenger, Betahistine, Therapy, Semaphore, AVS, Dizziness, AAV, Tinnitus, Heqet, Rhinitis, Central nervous system, Clinical trial, Small RNA, Sale, Cancer, EDT, Liver, Patient, Rheumatoid arthritis, Histamine, Regeneration

HAMILTON, BERMUDA -- April 10, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided a business update and reported its full year 2023 financial results.

Key Points: 
  • "Altamira emerged from the 2023 business year as a stronger and more focused company," commented Thomas Meyer, Altamira Therapeutics' founder, Chairman, and CEO.
  • "We keep progressing with our RNA delivery business, concluding recently our second collaboration agreement with another exciting biotech company.
  • Altamira expects to make further progress in 2024 with the strategic repositioning by partnering its inner ear therapeutics assets.
  • Altamira’s Senior Management will hold an investor call today, Wednesday, April 10, 2024, at 8:30 a.m. EDT to discuss its business update and full-year 2023 results.

Progress Software Corp. Announcement under the Irish Takeover Rules

Retrieved on: 
fredag, april 5, 2024
ACT, MAKE, RDBMS, OpenEdge, ANY, MarkLogic, Organization, Semaphore, SQL, FIRM, RAG, Acquisition, JDBC, AI, TCO, MADE, LTS, IRISH, Progress, ABL, ODBC, NOT, MariaDB

BURLINGTON, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- As was announced on 26 March, 2024, Progress Software Corp. (“Progress”) has expressed interest in acquiring MariaDB plc (“MariaDB”), via an announcement under Rule 2.4 of the Takeover Rules. Why do we believe this acquisition makes sense for Progress, for MariaDB customers and developers and for existing Progress customers and shareholders?

Key Points: 
  • THIS IS AN ANNOUNCEMENT UNDER THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 (THE "TAKEOVER RULES").
  • IT IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE TAKEOVER RULES.
  • BURLINGTON, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- As was announced on 26 March, 2024, Progress Software Corp. (“Progress”) has expressed interest in acquiring MariaDB plc (“MariaDB”), via an announcement under Rule 2.4 of the Takeover Rules.
  • Why do we believe this acquisition makes sense for Progress, for MariaDB customers and developers and for existing Progress customers and shareholders?

Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines

Retrieved on: 
måndag, mars 25, 2024
Semaphore, Cell, Patient, RNA, Messenger, Doctor of Philosophy, Infection, Antibody, Therapy, Vaccine

Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has entered into a collaboration agreement with Univercells Group (“Univercells”) to evaluate the use of the Company’s proprietary SemaPhore platform for the delivery of mRNA vaccines.

Key Points: 
  • Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has entered into a collaboration agreement with Univercells Group (“Univercells”) to evaluate the use of the Company’s proprietary SemaPhore platform for the delivery of mRNA vaccines.
  • Univercells is a global life sciences company creating platforms for developing and manufacturing biologics, including mRNA vaccines and therapeutics, in a simple, scalable and cost-efficient way.
  • Should the experiments prove successful, Univercells and Altamira intend to discuss and negotiate a commercial agreement for the development and manufacturing of nanoparticle-based mRNA vaccines using Univercells’ production platform.
  • “We are thrilled to initiate this collaboration with Univercells to explore SemaPhore as a delivery vehicle for mRNA vaccines”, commented Covadonga Pañeda, PhD, Altamira’s Chief Operating Officer.

Progress Receives 2024 Emotional Footprint Award for Metadata Management from SoftwareReviews

Retrieved on: 
tisdag, mars 19, 2024
Growth, Semaphore, Knowledge, Research, Software, PRGS, Performance, Progress, Metadata, Robert Shaye

BURLINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Progress (Nasdaq: PRGS), the trusted provider of infrastructure software, today announced that Progress® Semaphore™, its metadata management and semantic AI platform, was named a Champion in SoftwareReviews’ 2024 Metadata Management Emotional Footprint Awards. The Emotional Footprint Awards evaluate and rank products based on emotional response ratings from IT and business professionals. Progress achieved the highest score of all ranked companies.

Key Points: 
  • BURLINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Progress (Nasdaq: PRGS), the trusted provider of infrastructure software, today announced that Progress® Semaphore™ , its metadata management and semantic AI platform, was named a Champion in SoftwareReviews’ 2024 Metadata Management Emotional Footprint Awards .
  • The Emotional Footprint Awards evaluate and rank products based on emotional response ratings from IT and business professionals.
  • SoftwareReviews , a division of IT research and consulting firm Info-Tech Research Group , applies an emotional footprint methodology to aggregate scores across 26 dimensions of the vendor-client relationship and product effectiveness.
  • The result is a Net Emotional Footprint score—representing overall user sentiment.

Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit

Retrieved on: 
måndag, januari 8, 2024
RNA, JW Marriott Hotels, Protein, Neoplasm, Tumor microenvironment, Atherosclerosis, Messenger, WNT16, Aortic aneurysm, SOD2, Tissue, Osteoarthritis, Therapy, DNMT3B, Rheumatoid arthritis, Inflammation, Cancer, Semaphore, Vaccine

HAMILTON, BERMUDA Jan. 8, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced today that it will be presenting at the 3rd Annual mRNA-Based Therapeutics Summit, being held January 23-25 at the JW Marriott Hotel, Berlin.

Key Points: 
  • Altamira’s two flagship programs, AM-401 and AM-411, designed for KRAS-driven cancer and rheumatoid arthritis, serve to demonstrate the technology’s capability to enhance therapeutic efficacy
    HAMILTON, BERMUDA Jan. 8, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, announced today that it will be presenting at the 3rd Annual mRNA-Based Therapeutics Summit, being held January 23-25 at the JW Marriott Hotel, Berlin.
  • Covadonga Pañeda, Ph.D., the Company's Chief Operating Officer, will give a presentation at the conference titled, "Delivery of therapeutic RNA in inflammation and cancer using peptide-based nanoparticles”.
  • “However, even the most powerful mRNA therapeutic is useless if it is not delivered safely and effectively into target cells, which has remained one of the key challenges for non-hepatic targets to date.
  • SemaPhore™, Altamira’s peptide-based delivery platform for mRNA, has been successfully tested so far in vivo in models of osteoarthritis (WNT16, DNMT3B), atherosclerosis (p27Kip1), aortic aneurysm (SOD2), and tumor microenvironment (ZBTB46).

Progress Wins Gold in the 2023 SoftwareReviews Data Quadrant Awards for Metadata Management

Retrieved on: 
tisdag, december 12, 2023
Progress, Metadata management, Metadata, Software, Research, Gold, Semaphore, PRGS, Knowledge, Organization

BURLINGTON, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Progress (Nasdaq: PRGS), the trusted provider of infrastructure software, today announced that Progress® Semaphore™, its metadata management and semantic AI platform, has been recognized as a gold medalist and overall leader in the 2023 Metadata Management Data Quadrant from SoftwareReviews, a division of IT research and consulting firm Info-Tech Research Group. The data in the report is collected from real end users, providing a comprehensive evaluation of popular products in the Metadata Management market to create a holistic, unbiased view that helps prospective purchasers make better decisions.

Key Points: 
  • The data in the report is collected from real end users, providing a comprehensive evaluation of popular products in the Metadata Management market to create a holistic, unbiased view that helps prospective purchasers make better decisions.
  • "It’s an honor to be recognized as the leader in the 2023 Metadata Management Data Quadrant, particularly since the ranking is determined by those who matter to us most—genuine users,” said John Ainsworth, Executive Vice President, General Manager, Application and Data Platform, Progress.
  • Semaphore removes layers of information complexity and enables organizations to use enterprise data not just for knowledge but with the power of wisdom to act faster.
  • A complimentary copy of the 2023 Metadata Management Data Quadrant report is available here .

FII Institute's Global PRIORITY Summit Closes with Another Round of Unexpected Conversations To Shape the New Global Order

Retrieved on: 
torsdag, april 6, 2023
WeWork, Ethics, AI, Hope, Bloomberg L.P., Semaphore, Investment, IISS

MIAMI, April 6, 2023 /PRNewswire/ -- FII Institute's Global PRIORITY Summit in Miami closed with disruptive and unexpected conversations on peace and prosperity, upcoming big ideas for investments, AI ethics and risks, space as a new superpower, trust in the media - and hope. 

Key Points: 
  • The second day of FII Institute's Global PRIORITY Summit was a continuation of unexpected conversations as the over 700 delegates heard from brilliant minds across industries on creating a roadmap for the future.
  • MIAMI, April 6, 2023 /PRNewswire/ -- FII Institute's Global PRIORITY Summit in Miami closed with disruptive and unexpected conversations on peace and prosperity, upcoming big ideas for investments, AI ethics and risks, space as a new superpower, trust in the media - and hope.
  • Shervin Pishevar hosted Dr. Alan Baratz and John Quinn to share timely insights into the future and risks of AI.
  • The FII Institute's Global Priority Summit will be returning to Miami in March 2024 and looks forward to continuing the dialogue across its platforms.

FII Institute's Global PRIORITY Summit Closes with Another Round of Unexpected Conversations To Shape the New Global Order

Retrieved on: 
torsdag, april 6, 2023
WeWork, Ethics, AI, Hope, Bloomberg L.P., Semaphore, Investment, IISS

MIAMI, April 6, 2023 /PRNewswire/ -- FII Institute's Global PRIORITY Summit in Miami closed with disruptive and unexpected conversations on peace and prosperity, upcoming big ideas for investments, AI ethics and risks, space as a new superpower, trust in the media - and hope. 

Key Points: 
  • The second day of FII Institute's Global PRIORITY Summit was a continuation of unexpected conversations as the over 700 delegates heard from brilliant minds across industries on creating a roadmap for the future.
  • MIAMI, April 6, 2023 /PRNewswire/ -- FII Institute's Global PRIORITY Summit in Miami closed with disruptive and unexpected conversations on peace and prosperity, upcoming big ideas for investments, AI ethics and risks, space as a new superpower, trust in the media - and hope.
  • Shervin Pishevar hosted Dr. Alan Baratz and John Quinn to share timely insights into the future and risks of AI.
  • The FII Institute's Global Priority Summit will be returning to Miami in March 2024 and looks forward to continuing the dialogue across its platforms.

Altamira Therapeutics’ SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal Model

Retrieved on: 
onsdag, mars 22, 2023
Nanoparticle, Semaphore, Therapy, Neoplasm, Altamira, Research, Zinc finger, Domain, Cell, RNA, Immunotherapy, Washington University in St. Louis, Messenger, Sarcoma, Animal, BTB, Manuscript, Pathology, TME, Washington University School of Medicine, Tumor microenvironment, Vaccine, St. Louis

Expression of the ZBTB46 gene with SemaPhore was associated with an immunostimulatory tumor microenvironment (TME), and it was potentiated when combined with anti-PD1 immune checkpoint inhibition.

Key Points: 
  • Expression of the ZBTB46 gene with SemaPhore was associated with an immunostimulatory tumor microenvironment (TME), and it was potentiated when combined with anti-PD1 immune checkpoint inhibition.
  • In contrast, enforced ZBTB46 expression mitigated the pro-tumor TME features and restricted tumor growth, suggesting ZBTB46 as a potential target for tumor treatment.
  • In a next step, the group tested the systemic delivery of ZBTB46 mRNA with Altamira’s peptide-based SemaPhore nanoparticles in mouse models of sarcoma and metastatic breast cancer to boost ZBTB46 expression.
  • The treatment sustained ZBTB46 expression in tumor-dendritic cells and -endothelial cells and resulted in the restriction of tumor growth associated with an immunostimulatory TME.

Sema4 Assumes Management and Control of Melody Capital Partners LP

Retrieved on: 
fredag, mars 17, 2023
Professional Services, Technology, Other Technology, Finance, Asset Management, Consulting, ACO, C.A., House, Security (finance), Melody, Semaphore

2022-0008-PAF) on February 10, 2023.

Key Points: 
  • 2022-0008-PAF) on February 10, 2023.
  • Melody Capital Partners manages private investment funds that pursued a private lending and credit strategy.
  • The Melody investment funds are no longer raising or deploying capital, and Semaphore will manage the windup of the Melody investment funds to maximize returns for Melody investors.
  • The Semaphore appointment and assumption of management and control of the Melody private investment funds received unanimous consent of all representatives of the investors of the Melody private investment funds.